

Psychiatric Morbidity in a Sample of Egyptian Patients with Selected Cardiovascular and Endocrinal Diseases at Ain-Shams University Hospital

A thesis submitted for partial fulfillment of
M.D, Degree in Psychiatry

By

Al-Shayma Aly Hassan Radwan

M.B.B.Ch., M.Sc. Ain Shams University

Supervised by

Prof. Ahmed Mahmoud Okasha

Professor of Psychiatry

Faculty of Medicine Ain-Shams University

Prof. Mohamed

Fahmy Abdel Aziz

Professor of Internal Medicine

Faculty of Medicine

Ain-Shams University

Prof. Mohamed

Hamed Ghanem

Professor of Psychiatry

Faculty of Medicine

Ain-Shams University

Prof. Tarek Ahmed

Mahmoud

Professor of Psychiatry

Faculty of Medicine

Ain-Shams University

Prof. Afaf Mohamed

Abdel Samei

Professor of Psychiatry

Faculty of Medicine

Ain-Shams University

**Faculty of Medicine
Ain-Shams University
Cairo, 2013**

**الإعتلال النفسي في عينة من المرضى المصريين المصابين
بأمراض القلب والأوعية الدموية وأمراض الغدد الصماء
بمستشفى عين شمس الجامعي**

رسالة توطئه للحصول على درجة الدكتوراه فى الطب النفسى مقدمة من

**الطبيبة /الشيءاء على حسن رضوان
تحت إشراف**

الأستاذ الدكتور/ أحمد محمود عكاشه

أستاذ أمراض المخ والاعصاب والطب النفسى
كلية الطب – جامعة عين شمس

الأستاذ الدكتور/

محمد حامد غانم

أستاذ أمراض المخ والاعصاب والطب
النفسى
كلية الطب – جامعة عين شمس

الأستاذ الدكتور/

محمد فهمي عبد العزيز

أستاذ الباطنه العامه
كلية الطب – جامعة عين شمس

الأستاذ الدكتور/

عفاف محمد عبد السميع

أستاذ أمراض المخ والاعصاب والطب
النفسى
كلية الطب – جامعة عين شمس

الأستاذ الدكتور/

طارق أحمد محمود

أستاذ أمراض المخ والاعصاب والطب
النفسى
كلية الطب – جامعة عين شمس

كلية الطب – جامعة عين شمس

2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
" قالوا سبحانك لا علم لنا
إلا ما علمتنا إنك أنت العليم الحكيم

صدق الله العظيم
سورة البقرة (32)

ACKNOWLEDGEMENT

*First and foremost, I feel always indebted to **Allah** the most kind and most merciful, as we owe to him for his great care and guidance in every step in our life, and who enabled me to accomplish this work.*

*I wish to express my greatest gratitude and ultimate thanks to **Prof. Ahmed Okasha** Professor of Psychiatry, Faculty of Medicine, Ain Shams University for accepting to supervise this work and for his valuable supervision and guiding comments. He generously devoted much of his precious time and provided unlimited in depth guidance, I sincerely appreciate all the encouragement and support given by him.*

*I am profoundly grateful to **Prof. Mohamed Ghanem**, Professor of Psychiatry, Faculty of medicine, Ain Shams University, for his close and kind supervision, his constant fatherly advice and support and scientific guidance, for his trust in my performance and my work.*

*I am deeply grateful to **Prof. Mohamed Fahmy**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, I am grateful for his helpful notes and valuable recommendations throughout this work. His constant guidance helped me to achieve this work.*

Acknowledgement

*To **Prof. Tarek Okasha**, Prof. of Psychiatry, Faculty of Medicine, Ain Shams University, I express my sincere appreciation for his patient guidance, constructive remarks and continuous support. He gave genuine and kind help to achieve the best of this work.*

*My sincere thanks and deep appreciation goes to **Prof. Afaf Mohamed**, Prof. of Psychiatry, Faculty of Medicine, Ain Shams University, for her valuable comments and constructive criticism, and meticulous revision of the thesis, helping me to accomplish this work the best it could be.*

I would like to extend my thanks to all my professors, colleagues and friends, so many of them influenced, encouraged and inspired me throughout the years.

Last but not least, I wish to express my love and respect to my parents, my husband and my sisters and brothers, for your endless love and care, for your valuable emotional support and continuous encouragement which brought the best out of me. I owe you all every achievement throughout my life.

Finally, my thanks should go to all the patients who were the subjects of this work and who cooperated in this research.

CONTENTS

	Page
List of tables	i
List of figures	iv
List of abbreviations	v
Introduction and Aim of the work	1
Review of Literature	7
<i>Chapter 1: Psychiatric morbidity in cardiovascular disease</i>	8
Session 1: Psychiatric morbidity in ischemic heart disease	8
○ <i>ISHD as a risk factor for development of psychiatric disorder</i>	8
○ <i>Psychiatric disorder as a risk factor for development of ISHD</i>	18
○ <i>Effect of psychiatric disorder on morbidity and mortality in ISHD</i>	37
○ <i>Effect of psychotropic medication on prognosis of ISHD</i>	42
Session 2: Psychiatric morbidity in heart failure	49
○ <i>HF as a risk factor for development of psychiatric disorder</i>	49
○ <i>Psychiatric disorder as a risk factor for development of HF</i>	53
○ <i>Effect of psychiatric disorder on morbidity and mortality in HF</i>	60
○ <i>Effect of psychotropic medication on prognosis of HF</i>	63
<i>Chapter 2: Psychiatric morbidity in endocrine disease</i>	67
Session 1: Psychiatric morbidity in diabetes mellitus	67
○ <i>DM as a risk factor for development of psychiatric disorder</i>	67
○ <i>Psychiatric disorder as a risk factor for development of DM</i>	73

Contents

○ <i>Effect of psychiatric disorder on morbidity and mortality in DM</i>	83
○ <i>Effect of psychotropic medication on prognosis of DM</i>	87
Session 2: : Psychiatric morbidity in thyroid diseases	90
○ <i>Thyroid dis. as a risk factor for development of psychiatric disorder</i>	90
○ <i>Psychiatric disorder as a risk factor for development of Thyroid dis.</i>	100
○ <i>Effect of psychotropic medication on prognosis of Thyroid dis.</i>	102
Subject and Method	109
Results	128
Discussion	216
Conclusion	280
Recommendations	283
Limitations of the study	286
Summary	288
References	301
Appendices	355
Arabic Summary	١

List of Tables		Page
Table 1	Depression and development/ increased morbidity and mortality in ISHD	28
Table 2	Cardiac effects of antidepressants affecting ISHD prognosis	47
Table 3	Side effects of antipsychotics	48
Table 4	Potential benefits and risks of SSRIs in chronic heart failure	66
Table 5	Killip classification	118
Table 6	NYHA classification	120
Table 7	Zulewski's clinical score for hypothyroidism	121
Table 8	Wayne's Index for diagnosis of hyperthyroidism	122
Table 9	The sociodemographic data of the medical patients	134
Table 10	The clinical profile of ISHD patients	138
Table 11	The clinical profile of HF patients	141
Table 12	The clinical profile of DM patients	144
Table 13	The clinical profile of Thyroid patients	147
Table 14	Prevalence of mood disorders in medical patients	152
Table 15	Prevalence of anxiety disorders in medical patients	155
Table 16	Relation of gender to psychiatric morbidities in medical patients	160
Table 17	Relation of age to psychiatric morbidities in medical patients	161
Table 18	Relation of education to psychiatric morbidities in medical patients	164
Table 19	Relation of occupation to psychiatric morbidities in medical patients	165

List of Tables		Page
Table 20	Relation of marital status to psychiatric morbidities in medical patients	168
Table 21	Relation of residence to psychiatric morbidities in medical patients	169
Table 22	Relation of social class to psychiatric morbidities in medical patients	170
Table 23	Relation of the type of ACS to psychiatric morbidities in ISHD patients	174
Table 24	Relation of pathological Q wave to psychiatric morbidities in ISHD patients	175
Table 25	Relation of duration of HF to psychiatric morbidities in HF patients	178
Table 26	Relation of Hepatic impairment as a complication of HF to psychiatric morbidities in HF patients	179
Table 27	Relation of treatment with ACEIs to psychiatric morbidities in HF patients	180
Table 28	Relation of Substance abuse to psychiatric morbidities in HF patients	182
Table 29	Relation of DM complications to psychiatric morbidities	183
Table 30	Relation of Neuropsychiatric FH to psychiatric morbidities in DM	185
Table 31	Relation of Substance abuse to psychiatric morbidities in DM patients	186
Table 32	Relation of T4 level to psychiatric morbidities in Thyroid patients	187
Table 33	GAF scores in psychiatric morbidities in ISHD,HF, DM and thyroid patients	193

List of Tables		Page
Table 34	Comparison of GAF scores between the different medical diseases and the different psuchiatric morbidities	198
Table 35	Socio-Demographic variables and relation to Quality of life score in ISHD and HF	202
Table 36	Sociodemographic variables and relation to Quality of life score in DM and thyroid diseases	204
Table 37	Clinical profile variables and relation to Quality of life score in ISHD	206
Table 38	Clinical profile variables and relation to Quality of life score in HF	207
Table 39	Clinical profile variables and relation to Quality of life score in DM	210
Table 40	Clinical profile variables and relation to Quality of life score in Thyroid disease	211

List of Figures		Page
Figure 1	Slope leading to cardiovascular events in patients using antipsychotics	35
Figure 2	Neurohormonal theory for development of HF in depression	56
Figure 3	Neuroendocrine mechanism for development of DM in depression	77
Figure 4	Psychiatric morbidity in ISHD patients	149
Figure 5	Psychiatric morbidity in HF patients	149
Figure 6	Psychiatric morbidity in DM patients	150
Figure 7	Psychiatric morbidity in Thyroid patients	150
Figure 8	GAF scores in psychiatric morbidities in ISHD patients	194
Figure 9	GAF scores in psychiatric morbidities in HF patients	195
Figure 10	GAF scores in psychiatric morbidities in DM patients	196
Figure 11	GAF scores in psychiatric morbidities in Thyroid patients	197
Figure 12	Comparison of GAF scores in psychiatric morbidities between the different medical diseases	199
Figure 13	Comparison of GAF scores between the different psychiatric morbidities in each medical disease	200

LIST of ABBREVIATIONS

5-HT	5-Hydroxytryptophan
ACS	Acute Coronary Syndrome
AD	Anxiety Disorder
ASD	Acute Stress Disorder
BAD	Bipolar Affective Disorder
BDI	Beck Depression Inventory
BMI	Body Mass Index
CABG	Coronary Artery Bypass Grafting
CAD	Coronary Artery Disease
CAPMAS	Central Agency for Public Mobilization and Statistics
CHD	Coronary Heart Disease
CRP	C-reactive protein
CVS	Cerebrovascular Stroke
D2	Dopamine 2
DM	Diabetes Mellitus
ED	Endothelial dysfunction
EF	Ejection Fraction
FPG	Fasting Plasma Glucose
FT4	Free Thyroxine 4
GAD	Generalized Anxiety Disorder
GAF	Global Assessment of Functioning
GHQ	General Health Questionnaire
HAM-A	Hamilton-Anxiety
HDL	High Density Lipoprotein
HF	Heart Failure
HPA	Hypothalamo-Pituitary-Adrenal

List of Abbreviations

HPT	Hypotalama-Pituitary- Thyroid
HR	Heart Rate
HRV	Heart Rate Variability
IDO	Indoleamine 2,3 Dioxygenase
IL	Interleukin
ISHD	Ischemic Heart Disease
LDL	Low Density Lipoprotein
LVEF	Left Ventricular Ejection Fracrction
MDD	Major Depressive Disorder
MI	Myocardial Infarction
NSRI	Norepinephrine Serotonin Reuptake Inhibitor
NYHA	New York Heart Association
OGTT	Oral Glucose Tolerance Test
OHG	Oral Hypoglycemics
PAF	Platelet Activating Factor
PCI	Percutaneous Coronary Intervention
PTSD	Post-Traumatic Stress Disorder
SCID-I	Structured Clinical Interview for DSM-IV Axis I Disorders
SNS	Sympathetic Nervous System
SPSS	Statistical Package for Social Science
SSRI	Selective Serotonin reuptake Inhibitor
TCA	Tricyclic Antidepressants
TNF	Tumor Necrosis Factor
TRH	Thyrotropin-releasing hormone
TSH	Thyroid Stimulating Hormone

INTRODUCTION

Cardiovascular disease is the leading cause of death in the United States and in third-world countries. According to World Health Organization's estimate, depression and cardiovascular disease will be the two major causes of disability-adjusted life years by the year 2030 (*Murray and Lopez, 1996*).

Egypt bears a heavy burden from cardiovascular disease. The Egyptian National Hypertension Project found an adjusted overall prevalence of coronary heart disease of 8.3%, and a prevalence of heart failure of 13.3% among the hypertensive cohort and 5.8% among the normotensive cohort (*Sharraf et al., 2003; Almahmeed et al., 2012*). The prevalence of coronary heart disease is promoted in turn by a high prevalence of cardiovascular risk factors, particularly smoking, hypertension, dyslipidemia, diabetes, and sedentary lifestyles (*Ibrahim et al., 2001*). The death rates resulting from ischemic heart disease in Egypt reached 21% of total deaths (*World Health Organization, 2004*).

Despite the high prevalence of depression in cardiovascular populations (18.5% according to *Van Melle et al., 2006*), depression often remains underdiagnosed and thus

undertreated due to following reasons. First, depression is often regarded as a normal, understandable and expected reaction to physical illness that does not require further investigation or attention. Moreover, healthcare providers are reluctant to communicate the diagnosis of depression to patients due to the social stigma associated with psychiatric disorder. Second, depression is underdiagnosed due to lack of knowledge of healthcare providers regarding its diagnosis, screening and treatment options (*Hirschfeld et al., 1997*).

Yet the diagnosis of depression in these patients is of extreme importance as depression has a major impact on mortality, morbidity and functional recovery in patients with cardiovascular diseases (*Carney et al., 2004*). Seventeen percent of the depressed patients had died 6 months post-infarct, compared to only 3% of the non-depressed, a relative hazard 3.5 times higher for depressed patients compared to non-depressed after correction for other cardiovascular risk factors (*Frasure-Smith et al., 1993*). Patients who showed depressive symptomatology in the absence of major depressive disorder did not show an elevated mortality risk at 6 months, yet, mortality rates were significantly higher at 12 months compared to non-depressed patients and, at 18 months, mortality rates of patients with depressed symptomatology did not significantly differ from mortality rates of those diagnosed with depressive disorder